Allschwil, Switzerland

Florian Richalet

This inventor holds 1 USPTO granted patent and 3 published patent applications and 1 EPO patent. Top assignee: Redona Therapeutics, Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Florian Richalet. Retrieved from https://idiyas.com/inventor/florian-richalet

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Florian Richalet - Innovator in Cancer Treatment

Introduction: Florian Richalet is an inventor based in Allschwil, Switzerland. He is currently associated with Redona Therapeutics, Inc., where he focuses on developing innovative solutions for cancer treatment. Despite having no granted patents to his name, his contributions to the field of pharmaceuticals are noteworthy.

Latest Patent Applications: Florian Richalet has filed several patent applications aimed at addressing cancer. One of his latest applications is for "Benzo[h]quinazolin-4-amine and thieno[3,2-h]quinazolin-4-amine derivatives for the treatment of cancer." This invention provides compounds that are designed to treat neoplastic diseases, particularly cancer. Another significant application is for "1,2,4-Oxadiazol-5-one derivatives for the treatment of cancer," which also focuses on compounds that can be used in cancer therapies.

Conclusion: Florian Richalet is a dedicated inventor whose work in cancer treatment showcases his commitment to advancing medical science. His innovative approaches have the potential to make a significant impact in the fight against cancer.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…